Drug Trial Radar · NCT03464019
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
Last checked: Nov 20, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,097
Actual
Start
Jun 18, 2018
Primary completion
Jan 20, 2023
Study completion Jan 20, 2023
Sponsor
- Lead sponsor
- Milestone Pharmaceuticals Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medpace, Inc.; IQVIA Biotech
- First posted
- Mar 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a three-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil nasal spray (NS) self-administered by participants who experienced an episode of paroxysmal supraventricular tachycardia (PSVT) in an at-home setting. NODE-301 Part 1 included participants that received the randomized study drug to treat an episode of PSVT until the 150th positively adjudicated PSVT episode. Part 2 (also referred as the RAPID study) included participants that did not receive the randomized study drug in Part 1 and newly enrolled participants until the 180th positively adjudicated PSVT episode in Part 2. The study continued for approximately 6 months after the 180th positively adjudicated PSVT episode in Part 2 and this extension is referred to as Part 3 (also referred to as RAPID Extension).
Conditions
- Paroxysmal Supraventricular Tachycardia
Interventions
EtripamilDrug
Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
PlaceboDrug
Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Etripamil Test DoseDrug
During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Time to Conversion of an Episode of PSVT to Sinus Rhythm (SR) After Study Drug Administration.Time frame: NODE-301 Part 1: Within 5 hours of start of study drug dosing. NODE-301 Parts 2 and 3: Within 30 minutes of start of study drug dosing.
Locations
161 sites in 9 countries. Site status is shown where the registry gives one.
Arizona Arrhythmia Research Center
Phoenix, Arizona
Arkansas Cardiology
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Medvin Clinical Research
Cerritos, California
North Coast Cardiolog
Encinitas, California
Titan Medical Research - Oceanside
Encinitas, California
Los Alamitos Cardiovascular
Los Alamitos, California
Amicis Research Center - Northridge
Northridge, California
RESPIRE Research
Palm Springs, California
South Denver Cardiology Associates, P.C
Littleton, Colorado
Cardiology Associates of Fairfield County
Norwalk, Connecticut
FWD Clinical Research
Boca Raton, Florida
Baptist Health Ambulatory Services d/b/a
Jacksonville, Florida
United Health Research, LLC
Miami, Florida
IACT Health
Columbus, Georgia
Piedmont Heart Institute- Fayetteville
Fayetteville, Georgia
Piedmont Heart Institute-Fayetteville
Fayetteville, Georgia
Georgia Arrythmia Consultants&Research Institute
Macon, Georgia
St. Luke's Idaho Cardiology Associates
Boise, Idaho
Idaho Catalyst Clinical Research
Idaho Falls, Idaho
AMITA Health Medical Group Heart & Vascular Elk Grpve Village
Elk Grove Village, Illinois
Parkview Physicians Group - Cardiology
Fort Wayne, Indiana
Mercy One Iowa Heart Center
West Des Moines, Iowa
Clinical Trials of America, LLC - Monroe, LA
West Monroe, Louisiana
MedStar Health Research Institute - Chesapeake Cardiovascular Associates
Baltimore, Maryland
Sparrow Clinical Research Institute
Lansing, Michigan
Revival Research Institute, LLC - Southgate, MI
Southgate, Michigan
Mercy Research
St Louis, Missouri
Cardiovascular Associates of the Delaware Valley - Elmer
Elmer, New Jersey
Cardiovascular Associates of the Delaware Valley
Haddon Heights, New Jersey
Atlantic Health System - Morristown Medical Center
Morristown, New Jersey
Columbia University
New York, New York
New York Presbyterian Hospital/Weill Cornell Medical Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Cary Research Group, LLC
Cary, North Carolina
Sanger Heart and Vascular Institute
Charlotte, North Carolina
The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute
Charlotte, North Carolina
Hatton Institute for Research & Education, Trihealth, Inc. - Cardiology
Cincinnati, Ohio
The Ohio State University (OSU) Wexner Medical Center
Columbus, Ohio
Rama Research LLC
Marion, Ohio
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.